Meeting
2013 ASCO Annual Meeting
Occurrence of HER2 amplification in EGFR-mutant lung adenocarcinoma with acquired resistence to EGFR-TKIs.
Authors
Giuseppe Altavilla
Medical Oncology University of Messina, Messina, Italy
Giuseppe Altavilla , Carmela Arrigo , Chiara Tomasello , Mariacarmela Santarpia , Patrizia Mondello , Sara Benecchi , Vincenzo Pitini
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer - Non-small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 31, 2013 (suppl; abstr 8047)
DOI
10.1200/jco.2013.31.15_suppl.8047
Abstract #
8047
Poster Bd #
33C
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
HER2 amplification in EGFR mutant NSCLC after acquired resistance (AR) to EGFR-directed therapies.
First Author: Bing Xia
Poster
2017 ASCO Annual Meeting
Investigating novel resistance mechanisms to third generation EGFR TKI osimertinib in non-small cell lung cancer patients using next generation sequencing.
First Author: Qiuxiang Ou
Poster
2013 ASCO Annual Meeting
LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung.
First Author: Yi Long Wu
Poster
2024 ASCO Annual Meeting
Survival outcomes and subgroup analyses derived from a phase III randomized trial comparing afatinib to chemotherapy in treatment-naïve non-small cell lung cancer with a sensitizing uncommon epidermal growth factor receptor mutation (ACHILLES/TORG1834).
First Author: Yuki Sato